Baricitinib AI-Discovered Repurposing for COVID

Title

Baricitinib AI-Discovered Repurposing for COVID

Content

BenevolentAI applies artificial intelligence and machine learning to every stage of the drug discovery process, from target identification to clinical development. The company uses natural language processing to extract meaningful information from biomedical literature at scale, recognizing patterns that help uncover disease drivers and identify hidden opportunities. Unsupervised learning approaches identify latent biological mechanisms influencing complex diseases from molecular or clinical datasets. BenevolentAI uses representation learning to encode molecules and disease concepts for AI prediction of protein binding and therapy identification. Graph neural networks, tensor factorization models, and transformer-based NLP embedding models are applied to learn meaningful biomedical representations. The company's all-in-human platform combines biomedical literature analysis with proprietary molecular and clinical data to identify novel drug targets. BenevolentAI has a proprietary knowledge graph covering millions of relationships between genes, proteins, diseases, and drugs. The platform has been used to identify potential treatments for amyotrophic lateral sclerosis (ALS), Parkinson's disease, and other complex neurological conditions.

URL